EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Treatments and Outcomes of Newly Diagnosed CD5‐Positive Diffuse Large B‐Cell Lymphoma: A Multi‐Institutional Observational Study

Yuma Nato, Kana Miyazaki iD, Dai Maruyama iD, Hiroyuki Takahashi, Kazutaka Sunami, Satsuki Murakami, Eiju Negoro, Yuri Miyazawa, Ilseung Choi iD, Takahiro Okada, Nobuyuki Takayama, Naoto Tomita und 25 weitere

Hematological Oncology · 2025-03 · 43 (2)

DOI: 10.1002/hon.70047 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, online erschienen am 12.02.2025. Verfasst von Yuma Nato und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematological Malignancies, Mie University Graduate School of Medicine, Tsu, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, CD5 Antigens. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Center Research and Development Fund, Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD5‐positive diffuse large B‐cell lymphoma (CD5+ DLBCL) is characterized by a poor prognosis and frequent central nervous system (CNS) relapse. Sandwich therapy comprising dose‐adjusted (DA)‐EPOCH‐R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab) and high‐dose methotrexate (HD‐MTX) (DA‐EPOCH‐R/HD‐MTX) showed excellent efficacy and manageable safety in a phase II study of patients diagnosed with stage II–IV CD5+ DLBCL. To validate the results of that study and elucidate the current state of treatment for CD5+ DLBCL, we retrospectively analyzed the outcomes of patients with CD5+ DLBCL diagnosed between 2016 and 2021 who received anthracycline‐containing chemotherapy with rituximab. Among the 346 patients evaluated, 62 (18%) received DA‐EPOCH‐R/HD‐MTX. The median follow‐up time was 43 months. In 55 patients with stage II–IV disease treated with DA‐EPOCH‐R/HD‐MTX, the 2‐year overall survival (OS), progression‐free survival, and cumulative incidence of CNS relapse were 87% (95% CI, 73%–94%), 76% (95% CI, 61%–86%), and 7.3% (95% CI, 2.4%–16%), respectively. There were no treatment‐related deaths. Febrile neutropenia occurred in 18 (33%) patients. Multivariate analysis of the 346 patients identified elevated serum lactate dehydrogenase levels, multiple extranodal involvement, no intrathecal MTX (IT‐MTX), and no DA‐EPOCH‐R/HD‐MTX as independent risk factors for OS. Only one CNS relapse event was observed in 28 patients who received both HD‐MTX and IT‐MTX. Our study provides real‐world data on the treatments and outcomes of a large number of patients. The favorable survival and manageable toxicity of DA‐EPOCH‐R/HD‐MTX have been validated in clinical settings. The use of HD‐MTX and IT‐MTX might be effective for preventing CNS relapse in patients with CD5+ DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsCD5 AntigensHumansMaleFemaleMiddle AgedAgedAdultRetrospective StudiesDoxorubicinVincristineMethotrexateCyclophosphamideAged, 80 and overSurvival RateRituximabTreatment OutcomePrognosisPrednisoneYoung AdultEtoposide

Stichwörter der Autor:innen

CD5 antigencentral nervous system neoplasmsdiffuse large B‐cell lymphomamethotrexateretrospective study

Substanzen

CD5 AntigensDoxorubicinVincristineMethotrexateCyclophosphamideRituximabPrednisoneEtoposide

Autor:innen und Institutionen

  • Department of Hematological Malignancies, Mie University Graduate School of Medicine, Tsu, Japan.
  • Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
  • Department of Hematology Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan.
  • Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Hematology, NHO Okayama Medical Center, Okayama, Japan.
  • Department of Hematology, Aichi Medical University, Nagakute, Japan.

ORCID-Profile: Kana Miyazaki, Dai Maruyama, Ilseung Choi, Motoko Yamaguchi

Förderung

  • National Cancer Center Research and Development Fund
  • Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research

Zitieren

APA

Nato, Y., Miyazaki, K., Maruyama, D., Takahashi, H., Sunami, K., Murakami, S., Negoro, E., Miyazawa, Y., Choi, I., Okada, T., Takayama, N., Tomita, N., Momose, S., Kaneda, Y., Yoshida, M., Gomyo, H., Toyama, K., Nishikori, M., Saito, A., …, & Yamaguchi, M. (2025). Treatments and Outcomes of Newly Diagnosed CD5‐Positive Diffuse Large B‐Cell Lymphoma: A Multi‐Institutional Observational Study. Hematological Oncology, 43(2). https://doi.org/10.1002/hon.70047

Vancouver

Nato Y, Miyazaki K, Maruyama D, Takahashi H, Sunami K, Murakami S, et al. Treatments and Outcomes of Newly Diagnosed CD5‐Positive Diffuse Large B‐Cell Lymphoma: A Multi‐Institutional Observational Study. Hematological Oncology. 2025;43(2). doi:10.1002/hon.70047

BibTeX
@article{Nato2025,
  author = {Nato, Yuma and Miyazaki, Kana and Maruyama, Dai and Takahashi, Hiroyuki and Sunami, Kazutaka and Murakami, Satsuki and Negoro, Eiju and Miyazawa, Yuri and Choi, Ilseung and Okada, Takahiro and Takayama, Nobuyuki and Tomita, Naoto and Momose, Shuji and Kaneda, Yuto and Yoshida, Masahiro and Gomyo, Hiroshi and Toyama, Kohtaro and Nishikori, Momoko and Saito, Akio and Hiraga, Junji and Masunari, Taro and Takahashi, Naoki and Makiyama, Junya and Suzuki, Tomotaka and Tsunemine, Hiroko and Takizawa, Jun and Kato, Takeharu and Masaki, Yasufumi and Fukuhara, Noriko and Okamoto, Masataka and Tawara, Isao and Asano, Naoko and Ohshima, Koichi and Izutsu, Koji and Kato, Koji and Suzuki, Ritsuro and Yamaguchi, Motoko},
  title = {Treatments and Outcomes of Newly Diagnosed CD5‐Positive Diffuse Large B‐Cell Lymphoma: A Multi‐Institutional Observational Study},
  journal = {Hematological Oncology},
  year = {2025},
  volume = {43},
  number = {2},
  doi = {10.1002/hon.70047}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche